more conservative dosing for renal patients using erythropoiesis-stimulating agents

You'll see more conservative dosing for renal patients using erythropoiesis-stimulating agents...Procrit, Epogen, Aranesp.

FDA no longer recommends targeting a specific hemoglobin concentration for these drugs in chronic kidney disease patients.

There's not an additional benefit to aiming for a hemoglobin over 11 g/dL...and it increases the risk of heart attack, stroke, and death.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote